IPP Bureau
Natac receives GMP certificate to manufacture for the pharmaceutical sector
By IPP Bureau - October 12, 2024
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
Akums launches dual action heartburn relief chewable tablet
By IPP Bureau - October 12, 2024
This product is categorized as antacids, antiflatulents and anti-Ulcerants
USFDA approves Pfizer’s marstacimab-hncq for treatment of hemophilia A or B
By IPP Bureau - October 12, 2024
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
SIBUR to provide raw materials to Russian medical industry
By IPP Bureau - October 12, 2024
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
Zydus receives final approval from USFDA for Paliperidone ER Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg
By IPP Bureau - October 11, 2024
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Alkem enters into licensing agreement with BioTherapeutics
By IPP Bureau - October 11, 2024
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
FDA approves Roche’s Itovebi for treatment of HER2-negative breast cancer with a PIK3CA mutation
By IPP Bureau - October 11, 2024
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Privi Speciality Chemicals gets USFDA certificate for camphor product
By IPP Bureau - October 11, 2024
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
OneSource unveils new brand identity at CPHI Milan
By IPP Bureau - October 11, 2024
Aims to achieve CDMO sales of US$ 400 million by 2028
WHO declares India has eliminated Trachoma as a public health problem in 2024
By IPP Bureau - October 10, 2024
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
India’s emergence as a hub for affordable medicines is commendable: Dr. Jitendra Singh
By IPP Bureau - October 10, 2024
We now rank 3rd in pharmaceutical production by volume and 14th by value
Biocon Biologics’ sponsored report suggests ways to increase adoption of Biosimilars in poor countries
By IPP Bureau - October 09, 2024
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Aurigene Oncology gets positive results of Phase 1 study for CAR-T cell therapy for multiple myeloma
By IPP Bureau - October 09, 2024
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
DKSH partners with R-Biomeds to bring oncology and thyroid treatments to Cambodia
By IPP Bureau - October 09, 2024
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
Vestige Marketing launches two innovative products
By IPP Bureau - October 09, 2024
Biotin Sublingual Spray and Melatonin Sublingual Spray to help consumers tackle health issues that come with today’s fast-paced life
